BioSpace News Archive

Geneoscopy Inc. today announced the enrollment of its first patients in the CRC-PREVENT pivotal trial.

Evelyn Wang, PhD has joined Circle Pharma as its Vice President of Translational Medicine and will lead Circle’s translational team in its development of macrocycle therapeutics against intractable cancer targets.

Medical device and technology company Lazurite Holdings LLC announced that its modular ArthroFree ™ wireless arthroscopic camera system has been recognized by the American Orthopaedic Society for Sport Medicine (AOSSM) as a winner of its inaugural annual ACE (Accelerating the Cutting Edge) Award recognizing cutting-edge innovation in the field of orthopedic sports medicine.

Neurana Pharmaceuticals, Inc. today announced participation at the William Blair Biotech Focus Conference. The conference takes place virtually July 14-15 th .

BerGenBio has presented a combined analysis of data from two Phase II studies investigating bemcentinib in hospitalised COVID-19 patients at the European Congress of Clinical Microbiology & Infectious Diseases (ECCMID).

The increasing cases of infectious diseases are a prime factor augmenting the growth of the global digital PCR and real-time PCR market during the forecast period set between 2020 and2030.

The term accountable care organizations represents modification in reimbursement from process based fee for service to fee for quality, disease and condition based repayment with capitated payments to health care delivery organizations on a per case and per capita basis. In order to be commercially operative as an accountable care organization, it needs to determine whether it is delivering an advanced quality of health care and upgraded proficiency.

MaxCyte, Inc. announced the public filing of a registration statement on Form S-1 with the U.S. Securities and Exchange Commission relating to a proposed dual listing of its shares of common stock on the Nasdaq Global Market under the symbol “MXCT.” As part of the proposed Nasdaq dual listing, MaxCyte is planning a public offering of shares of its common stock in the United States.

Biophytis SA, a clinical-stage biotechnology company focused on the development of therapeutics that are aimed at slowing the degenerative processes associated with aging and improving functional outcomes for patients suffering from age-related diseases, including severe respiratory failure in patients suffering from COVID-19 announces new positive preclinical data on Sarconeos in hamsters infected with SARS-CoV-2.

Inotrem S.A., a biotechnology company specializing in the development of immunotherapies targeting the TREM-1 pathway, announces that it has obtained authorization to pursue the clinical development of nangibotide up to registration in COVID-19 patients from both the French and Belgian competent authorities.